These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 21437249)

  • 1. Multiple cancer/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers.
    Chen YT; Ross DS; Chiu R; Zhou XK; Chen YY; Lee P; Hoda SA; Simpson AJ; Old LJ; Caballero O; Neville AM
    PLoS One; 2011 Mar; 6(3):e17876. PubMed ID: 21437249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer.
    Ademuyiwa FO; Bshara W; Attwood K; Morrison C; Edge SB; Karpf AR; James SA; Ambrosone CB; O'Connor TL; Levine EG; Miliotto A; Ritter E; Ritter G; Gnjatic S; Odunsi K
    PLoS One; 2012; 7(6):e38783. PubMed ID: 22761704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer-testis antigen expression in digestive tract carcinomas: frequent expression in esophageal squamous cell carcinoma and its precursor lesions.
    Chen YT; Panarelli NC; Piotti KC; Yantiss RK
    Cancer Immunol Res; 2014 May; 2(5):480-6. PubMed ID: 24795360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer-testis antigen expression in triple-negative breast cancer.
    Curigliano G; Viale G; Ghioni M; Jungbluth AA; Bagnardi V; Spagnoli GC; Neville AM; Nolè F; Rotmensz N; Goldhirsch A
    Ann Oncol; 2011 Jan; 22(1):98-103. PubMed ID: 20610479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of tumor-associated antigens in breast cancer subtypes.
    Curigliano G; Bagnardi V; Ghioni M; Louahed J; Brichard V; Lehmann FF; Marra A; Trapani D; Criscitiello C; Viale G
    Breast; 2020 Feb; 49():202-209. PubMed ID: 31869767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Significance of carbonic anhydrase IX protein expression in molecular subtyping of breast cancers].
    Li MP; Ren LF; Cai HG; Yang HY; Lu B; Zhang P; Bao L
    Zhonghua Bing Li Xue Za Zhi; 2013 Mar; 42(3):182-5. PubMed ID: 23769438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya.
    Sayed S; Moloo Z; Wasike R; Bird P; Oigara R; Govender D; Kibera J; Carrara H; Saleh M
    Breast; 2014 Oct; 23(5):591-6. PubMed ID: 25012047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre- and post- neoadjuvant chemotherapy in primary breast carcinoma: a single institutional experience.
    Kinsella MD; Nassar A; Siddiqui MT; Cohen C
    Int J Clin Exp Pathol; 2012; 5(6):530-6. PubMed ID: 22949935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α expression in invasive ductal breast cancer patients and correlations with prognosis.
    Yan J; Liu XL; Han LZ; Xiao G; Li NL; Deng YN; Yin LC; Ling LJ; Yu XY; Tan CL; Huang XP; Liu LX
    Asian Pac J Cancer Prev; 2015; 16(2):823-9. PubMed ID: 25684532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemistry subtypes (ER/PR/HER) of breast cancer: where do we stand in the West of Saudi Arabia?
    Khabaz MN
    Asian Pac J Cancer Prev; 2014; 15(19):8395-400. PubMed ID: 25339035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological characteristics of metaplastic breast cancer - analysis of the basic immunohistochemical profile and comparison with other invasive breast cancer types.
    Budzik MP; Patera J; Sobol M; Czerw AI; Deptała A; Badowska-Kozakiewicz AM
    Breast; 2019 Feb; 43():135-141. PubMed ID: 30553188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.
    Fernandes RC; Bevilacqua JL; Soares IC; Siqueira SA; Pires L; Hegg R; Carvalho FM
    Histopathology; 2009 Sep; 55(3):346-52. PubMed ID: 19723150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.
    Azizun-Nisa ; Bhurgri Y; Raza F; Kayani N
    Asian Pac J Cancer Prev; 2008; 9(4):553-6. PubMed ID: 19256737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical Expression of BRCA1 Protein, ER, PR and Her2/neu in Breast Cancer: A Clinicopathological Study.
    Hussein IA; Ahmed ST; Hameedi AD; Naji RZ; Alharbawi L; Alkhaytt M; Pity IS
    Asian Pac J Cancer Prev; 2020 Apr; 21(4):1025-1029. PubMed ID: 32334465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CT-X antigen expression in human breast cancer.
    Grigoriadis A; Caballero OL; Hoek KS; da Silva L; Chen YT; Shin SJ; Jungbluth AA; Miller LD; Clouston D; Cebon J; Old LJ; Lakhani SR; Simpson AJ; Neville AM
    Proc Natl Acad Sci U S A; 2009 Aug; 106(32):13493-8. PubMed ID: 19651608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic variables in invasive breast cancer: contribution of comedo versus noncomedo in situ component.
    Brower ST; Ahmed S; Tartter PI; Bleiweiss I; Amberson JB
    Ann Surg Oncol; 1995 Sep; 2(5):440-4. PubMed ID: 7496840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormone receptor and HER2 status in patients with breast cancer by races in southeastern Turkey.
    Kuzhan A; Adli M; Eryigit Alkis H; Caglayan D
    J BUON; 2013; 18(3):619-22. PubMed ID: 24065473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.